Literature DB >> 24393741

Mitochondrial cofactors in experimental Huntington's disease: behavioral, biochemical and histological evaluation.

Arpit Mehrotra1, Rajat Sandhir2.   

Abstract

The present study was carried out to evaluate the beneficial effect of mitochondrial cofactors; alpha-lipoic acid (ALA) and acetyl-l-carnitine (ALCAR) in 3-nitropropionic acid (3-NP) induced experimental model of Huntington's disease (HD). HD was developed by administering sub-chronic doses of 3-NP, intraperitoneally, twice daily for 17 days. The animals were assessed for their behavioral performance in terms of motor (spontaneous locomotor activity, narrow beam walk test, footprint analysis and rotarod test) and cognitive (elevated plus maze and T-maze tests) functions. 3-NP treated animals showed impairment in motor coordination such as decreased stride length, increased distance between inner toes, and increased gait angle. Increased transfer latency on elevated plus maze and T-maze tasks revealed cognition deficits in 3-NP treated animals. Increased lipid peroxidation and concomitant decrease in thiol levels were also observed. 3-NP administration also induced histopathological changes in terms of enhanced striatal lesion volume, presence of pyknotic nuclei and astrogliosis. However, combined supplementation with ALA+ALCAR to 3-NP administered animals for 21 days was able to efficiently improve behavioral deficits, attenuate oxidative stress and histological changes, suggesting a putative role of these two supplements if given together in ameliorating 3-NP induced impairments and thus could be engaged in managing HD.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  2,3,5-triphenyltetrazolium chloride; 3,3′-di-aminobenzidine; 3-NP; 3-nitropropionic acid; ALA; ALCAR; Acetyl-l-carnitine; Alpha-lipoic acid; Behavior; DAB; GFAP; GSH; HD; Huntington's disease; MDA; Mitochondria; TTC; acetyl-l-carnitine; alpha-lipoic acid; glial fibrillary acidic protein; glutathione; malondialdehyde

Mesh:

Substances:

Year:  2014        PMID: 24393741     DOI: 10.1016/j.bbr.2013.12.035

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  6 in total

1.  Mitochondrial modulators improve lipid composition and attenuate memory deficits in experimental model of Huntington's disease.

Authors:  Arpit Mehrotra; Abhilasha Sood; Rajat Sandhir
Journal:  Mol Cell Biochem       Date:  2015-09-15       Impact factor: 3.396

2.  Propensity of Withania somnifera to Attenuate Behavioural, Biochemical, and Histological Alterations in Experimental Model of Stroke.

Authors:  Abhilasha Sood; Aditya Kumar; Devinder K Dhawan; Rajat Sandhir
Journal:  Cell Mol Neurobiol       Date:  2015-12-30       Impact factor: 5.046

3.  Indian Ginseng (Withania somnifera) supplementation ameliorates oxidative stress and mitochondrial dysfunctions in experimental model of stroke.

Authors:  Abhilasha Sood; Arpit Mehrotra; Devinder K Dhawan; Rajat Sandhir
Journal:  Metab Brain Dis       Date:  2018-04-18       Impact factor: 3.584

4.  Abnormal Weight and Body Mass Index in Children with Juvenile Huntington's Disease.

Authors:  Alexander Tereshchenko; Michael McHugh; Jessica K Lee; Pedro Gonzalez-Alegre; Kaitlin Crane; Jeffrey Dawson; Peg Nopoulos
Journal:  J Huntingtons Dis       Date:  2015

5.  Schisandra chinensis Stem Ameliorates 3-Nitropropionic Acid-Induced Striatal Toxicity via Activation of the Nrf2 Pathway and Inhibition of the MAPKs and NF-κB Pathways.

Authors:  Eun-Jeong Kim; Minhee Jang; Min Jung Lee; Jong Hee Choi; Sung Joong Lee; Sun Kwang Kim; Dae Sik Jang; Ik-Hyun Cho
Journal:  Front Pharmacol       Date:  2017-09-29       Impact factor: 5.810

6.  C60 Fullerene Reduces 3-Nitropropionic Acid-Induced Oxidative Stress Disorders and Mitochondrial Dysfunction in Rats by Modulation of p53, Bcl-2 and Nrf2 Targeted Proteins.

Authors:  Olga O Gonchar; Andriy V Maznychenko; Olena M Klyuchko; Iryna M Mankovska; Kamila Butowska; Agnieszka Borowik; Jacek Piosik; Inna Sokolowska
Journal:  Int J Mol Sci       Date:  2021-05-21       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.